trending Market Intelligence /marketintelligence/en/news-insights/trending/_yrrx_1j_ul5tuolxlfbyw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US judge reverses $2.54B hepatitis C drug patent verdict against Gilead

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


US judge reverses $2.54B hepatitis C drug patent verdict against Gilead

A federal judge in Delaware ruled that Gilead Sciences Inc. no longer has to pay Merck & Co. Inc. a record $2.54 billion in damages under a previous patent infringement verdict, Reuters reported.

In December 2016, a federal jury in a U.S. District Court in Delaware ordered Gilead to pay the amount after deciding that its blockbuster hepatitis C therapies Sovaldi and Harvoni infringed a Merck patent. The jurors found the patent, which covers hepatitis C treatments, valid.

U.S. District Judge Leonard Stark reversed the verdict Feb. 16, ruling Merck's patent invalid because it failed to meet a rule requiring the company to disclose how to make the drug the patent covered without undue experimentation.

Merck plans to appeal the verdict, Reuters reported, citing a statement by the New Jersey-based drugmaker. Merck acquired the patent when it bought Idenix Pharmaceuticals Inc. in 2014.